Sanofi Receives Antitrust Clearances in U.S., Germany for Ablynx Acquisition
01 March 2018 - 9:19PM
Dow Jones News
By Sonia Amaral Rohter
Sanofi SA (SAN.FR) said Thursday that it has received antitrust
clearances in the U.S. and Germany in connection with its proposed
acquisition of Ablynx NV (ABLX.BT).
Sanofi said that a waiting period for its proposed acquisition
of Ablynx has expired without objections being raised. Under the
U.S. Hart-Scott-Rodino Antitrust Improvements Act, parties to
certain transactions must submit notification to the country's
Federal Trade Commission and Department of Justice and wait before
the transaction can be completed.
The proposed acquisition has also been cleared by the Federal
Cartel Office of Germany, the FCO, the French pharmaceutical
company said.
With the expiration of the waiting period and the FCO clearance,
"the condition to the offers relating to antitrust approvals has
been satisfied," Sanofi said.
In late January, Sanofi agreed to buy Belgian biopharmaceutical
company Ablynx for 3.9 billion euros ($4.76 billion).
The closing of the offers is still subject to various
conditions, Sanofi said.
Write to Sonia Amaral Rohter at
sonia.amaralrohter@dowjones.com
(END) Dow Jones Newswires
March 01, 2018 05:04 ET (10:04 GMT)
Copyright (c) 2018 Dow Jones & Company, Inc.
Sanofi (NASDAQ:SNY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Sanofi (NASDAQ:SNY)
Historical Stock Chart
From Apr 2023 to Apr 2024